Epilepsy

What makes us human? Detailed cellular maps of the entire human brain reveal clues

Retrieved on: 
Thursday, October 12, 2023
Neuroscience, Knowledge, Senior, 3D, Allen Institute, Brain, Neocortex, Cell, Neuron, Chimpanzee, BRAIN, Epilepsy, Myenteric plexus, Neurosurgery, Karolinska Institute, Patient, Visual cortex, Human Cell Atlas, Allen Institute for Brain Science, BRAIN Initiative, Primate, Gene, Research, Molecular biology, Catalog, Mouse, Bangladesh Technical Education Board, Science Advances, Tissue, Human, Genomics, Science Translational Medicine, Mammal, NIH, Mobile phone, Medical imaging, Truffle, Science

SEATTLE, Oct. 12, 2023 /PRNewswire/ -- Scientists have just unveiled a massive effort to understand our own brains and those of our closest primate relatives.

Key Points: 
  • It's a huge leap from previously published work, with studies and data that reveal new insights about our nervous systems' cellular makeup across many regions of the brain and what is distinctive about the human brain.
  • It was brought together and is funded by the National Institutes of Health's Brain Research Through Advancing Innovative Neurotechnologies ® (BRAIN) Initiative.
  • Where the single region studies found over 100 different brain cell types, the newly released data shows thousands of different kinds of brain cells across the entire brain.
  • This was one of the first human brain studies to compare a large number of individual people using single-cell techniques.

NEURELIS TO PRESENT ANALYSES OF VALTOCO® (diazepam nasal spray) CIV AT THE 52nd CHILD NEUROLOGY SOCIETY ANNUAL MEETING

Retrieved on: 
Wednesday, October 4, 2023
Epilepsy, Seizure, Safety, Fed, Quality of life, Research, Absorption, Neurology, Patient, Child, CBD, Effectiveness, Ageing, Health, FDA, Division of Program Coordination, Planning, and Strategic Initiatives, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Diazepam, Pharmaceutical industry, Dietary supplement, Gustav Neuring

SAN DIEGO, Oct. 4, 2023 /PRNewswire/ -- Neurelis, Inc., today announced additional findings from the post hoc analysis of the long-term phase 3 safety study of VALTOCO® (diazepam nasal spray) in a pediatric population, aged 6-17 years, as well as an analysis of real-world data on impact of administration of rescue medication on seizure timing.  A total of four posters will be presented at the 52nd Child Neurology Society Annual Meeting in Vancouver, BC, Canada, October 4 – 7, 2023. The Child Neurology Society's mission is to raise awareness about the importance of child neurologists and the health needs of children with chronic neurological conditions.

Key Points: 
  • A total of four posters will be presented at the 52nd Child Neurology Society Annual Meeting in Vancouver, BC, Canada, October 4 – 7, 2023.
  • The Child Neurology Society's mission is to raise awareness about the importance of child neurologists and the health needs of children with chronic neurological conditions.
  • "This data brings us one step closer to addressing seizures acutely to improve the quality of life for people with epilepsy."
  • "We are pleased to present these findings to help the child neurology community identify advanced treatment options," said Enrique Carrazana, Neurelis Senior Vice President, Strategic Initiatives.

EEG Analysis and Animal Behavior in CNS Drug Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 4, 2023
Epilepsy, Central nervous system, Depression, Schizophrenia, Electroencephalography, Neuropharmacology, Attention deficit hyperactivity disorder predominantly inattentive, Non-24-hour sleep–wake disorder, Neuroscience, Toxicity, Biomarker, Doctor of Philosophy, CNS, Attention deficit, Pain, Risk, EEG, Drug discovery, Alzheimer's disease, Medical imaging, Pharmaceutical industry, Generic drug

TORONTO, Oct. 4, 2023 /PRNewswire-PRWeb/ -- EEG analysis (Electroencephalography) is becoming a promising translatable biomarker for predicting the likelihood that novel therapies and compounds will exhibit clinical efficacy early in preclinical development.

Key Points: 
  • In this free webinar, gain insights into electroencephalography (EEG) analysis as physiological endpoints to facilitate drug discovery, lead optimization or candidate compound selection as well as to serve for go/no go decisions.
  • The featured speaker will share case studies of EEG-based signatures in correlation with animal behavior which potentially may validate the EEG as endpoints for a set of translatable biomarkers bridging preclinical and clinical programs.
  • EEG-based signatures represent promising preclinical screens to quickly determine CNS penetration, drug-target engagement, evidence of efficacy, pharmacokinetic/pharmacodynamic profile, CNS safety and toxicity and pro-convulsant risk.
  • Join this webinar to gain insights into EEG analysis as physiological endpoints to facilitate drug discovery for CNS diseases.

A Quarter Century of Disease-Focused Neuroscience

Retrieved on: 
Tuesday, October 3, 2023
Epilepsy, San Francisco, Huntington's disease, Central nervous system, Therapy, Prevalence, Stanford University, Apolipoprotein, Biogen, Biotechnology, University of California, San Francisco, Brain, Research, DSM-IV codes, Multiple sclerosis, Fairmont San Francisco, AstraZeneca, Eli Lilly, Neuroscience, Amyloid, Parkinson's disease, UC, Myenteric plexus, Patient, Tau, Trustee, SAN, Gladstone Institutes, Spectrum, Blood, Weill Cornell Medicine, Sanofi, BMS, Merck, Takeda Pharmaceutical Company, Disease, Pharmaceutical industry, Vaccine, Nursing, Lundbeck, Alzheimer's disease, Genentech, MD, William Ewart Gladstone

SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- A quarter century ago, in September 1998, Gladstone Institutes launched the Gladstone Institute of Neurological Disease. In 2023, it brought together investigators and alumni to celebrate the institute's 25th anniversary, reflect on landmark scientific achievements, and look ahead at the future of disease-focused neuroscience.

Key Points: 
  • SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- A quarter century ago, in September 1998, Gladstone Institutes launched the Gladstone Institute of Neurological Disease.
  • In 2023, it brought together investigators and alumni to celebrate the institute's 25th anniversary, reflect on landmark scientific achievements, and look ahead at the future of disease-focused neuroscience.
  • As populations around the world are living longer, aging-related neurodegenerative disorders have been rising in prevalence at an unprecedented pace.
  • These landmark discoveries, and many others, were presented on September 15, 2023, as part of the symposium "Disease-Focused Neuroscience: From Discovery to Translation."

NEURELIS WINS MULTIPLE AWARDS AS A BEST PLACE TO WORK IN SOUTHERN CALIFORNIA

Retrieved on: 
Tuesday, October 3, 2023
Epilepsy, Human resources, CIV, The Last Best Place, Organization, BCG, Southern California, Patient, SAN, Growth, Entrepreneurship, San Diego Business Journal, FDA, Environment, Pharmaceutical industry, Gustav Neuring

SAN DIEGO, Oct. 3, 2023 /PRNewswire/ -- Neurelis, Inc. is pleased to announce it has been named one of the Best Places to Work in SoCal 2023 by Best Companies Group (BCG), a BridgeTower Media Company, for the second consecutive year. The Company also has been named to the 2023 list of Best Places to Work in San Diego by the San Diego Business Journal. These award designations were made based on employee feedback and reflect the talented team of dedicated professionals at Neurelis. 

Key Points: 
  • SAN DIEGO, Oct. 3, 2023 /PRNewswire/ -- Neurelis, Inc. is pleased to announce it has been named one of the Best Places to Work in SoCal 2023 by Best Companies Group (BCG), a BridgeTower Media Company, for the second consecutive year.
  • The Company also has been named to the 2023 list of Best Places to Work in San Diego by the San Diego Business Journal.
  • These award designations were made based on employee feedback and reflect the talented team of dedicated professionals at Neurelis.
  • As a team, Neurelis is fully committed to partner with professional and patient advocacy organizations to significantly advance the care of people suffering from neurological conditions.

First Choice Neurology Named to Modern Healthcare’s 2023 Top Innovators List

Retrieved on: 
Tuesday, October 3, 2023
Software, Telemedicine, Virtual Medicine, Internet, Managed Care, Health, Hospitals, Technology, Other Health, Epilepsy, FCN, Stroke, New Orleans Central Business District, Neurology, Multiple sclerosis, Organization, Interface (computing), Dementia, Hospital, Patient, Sleep, Pharmaceutical industry, Nursing, Modern Healthcare

First Choice Neurology (FCN), the largest U.S. neurology specialty group practice, today announced that it has been recognized by Modern Healthcare as one of the Top Innovators for 2023.

Key Points: 
  • First Choice Neurology (FCN), the largest U.S. neurology specialty group practice, today announced that it has been recognized by Modern Healthcare as one of the Top Innovators for 2023.
  • The profiles of the honorees are featured in the Sept. 18, 2023, issue of Modern Healthcare magazine and online at ModernHealthcare.com/Top-Innovators .
  • FCN operates more than 50 care centers and is affiliated with 45-plus major hospitals in multiple Florida counties.
  • “First Choice Neurology’s pioneering journey and commitment to digital health transformation is inspiring to all providers wanting to empower their patients and achieve operational objectives.”

Safer and more Effective Brain Interfaces: First in Human Brain Recordings Achieved by Neurosoft Bioelectronics

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Medical Devices, Neurology, Health Technology, Clinical Trials, Biotechnology, Epilepsy, Swiss, Swiss Federal Institute of Technology, Digital Writing and Research Lab, Tinnitus, Deafness, Auditory cortex, Brain, Multimedia, Research, Biomarker, Trial of the century, Paralysis, DSM-IV codes, Wyss Center for Bio and Neuroengineering, Electrode, Patient, Traumatic brain injury, Memorial Hermann Health System, Hematoma, EPFL, FDA, Swiss Federal Institute of Aquatic Science and Technology, Safety, Hippocampus, Medical imaging, Medical device, Nursing

Two epileptic patients and one brain tumour patient have undergone a successful surgery, while detailed recordings were obtained in parallel from the surface of the brain.

Key Points: 
  • Two epileptic patients and one brain tumour patient have undergone a successful surgery, while detailed recordings were obtained in parallel from the surface of the brain.
  • Furthermore, the application of Neurosoft Bioelectronics’ electrodes presents the possibility of uncovering supplementary biomarkers which could significantly help in providing more effective and safer treatments of brain disorders for future patients.
  • Amidst these challenges, Neurosoft Bioelectronics' soft and elastic electrodes present themselves as a promising alternative to existing invasive solutions.
  • The Neurosoft Bioelectronics team has also been studying how these electrodes could address indications like severe tinnitus.

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

Retrieved on: 
Monday, October 2, 2023
Epilepsy, Seizure, Tremor, Central nervous system, University, Event, Week, Le bonheur, DSM-IV codes, NYU, Aes, New York University Grossman School of Medicine, Media, Part, CNS, Șaeș, Essential tremor, Professor, Patient, Master of Science, Webcast, FANA, Neurology, Encephalopathy, Propranolol, R, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FAAN, Food, Medical imaging, Pharmaceutical industry, Drug, Nursing, Praxis

BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on its clinical portfolio at the company’s R&D Day. Praxis’ leaders were joined by two esteemed key opinion leaders in movement disorders and epilepsy, respectively: Alberto J. Espay, M.D., MSc, FAAN, FANA, Professor and Endowed Chair of the James J. and Joan A. Gardner Center for Parkinson’s Disease at the University of Cincinnati, as well as Jacqueline French, M.D., Professor of Neurology at NYU Grossman School of Medicine and President, Director and Founder of the Epilepsy Study Consortium.

Key Points: 
  • Phase 3 (Essential3) program for ulixacaltamide initiating this quarter with mADL11 as primary endpoint; nearly 600 patients have already expressed interest in participating
    BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on its clinical portfolio at the company’s R&D Day.
  • “We were thrilled to be able to share important updates from our portfolio.
  • Especially exciting is the early efficacy data we have seen with our PRAX-222 program in SCN2A gain-of-function developmental epilepsies and encephalopathies (DEEs).
  • A replay of the R&D day webcast will be available through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com for the next 90 days.

IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec

Retrieved on: 
Monday, October 2, 2023
Professional Services, Health, General Health, Pharmaceutical, Small Business, Neurology, Other Science, Research, Science, Clinical Trials, Finance, Epilepsy, Volunteering, PK, Male, IndiGo, Drug development, PD, Clinical trial, Pharmacokinetics, IAMA, CTA, SAD, Toxicity, MBA, Female, DSM-IV codes, NKCC1, Spectrum, MAD, FIH, Therapy, IND, Safety, Pharmaceutical industry, EU, Evotec

IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that it has signed a multi-phase agreement with Evotec, which offers integrated drug development solutions.

Key Points: 
  • IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that it has signed a multi-phase agreement with Evotec, which offers integrated drug development solutions.
  • The agreement expands the companies' existing relationship, which entails collaborating on IND-enabling preclinical studies for IAMA-6.
  • IAMA plans to submit a CTA filing in the EU and initiate a Phase 1 clinical trial by the end of 2023.
  • "We look forward to adding further rapid, efficient, and seamlessly integrated services to build on our successful relationship with IAMA."

Should I be getting my vitamin D levels checked?

Retrieved on: 
Monday, October 2, 2023
Epilepsy, Differentiable function, Anticonvulsant, DNA, Radiation, Obesity, Diet, Vitamin D deficiency, Sun, Skin cancer, Research, Infection, Multiple sclerosis, Pigment, UVB, Calcium, Vitamin D, Sunlight, Metabolism, Laboratory, Time, Risk, Kidney, Osteomalacia, Liver, Mortality, Rickets, Health, Phosphorus, Skin, Conditional sentence, DNA repair, Dietary supplement, Vaccine, Calcifediol

Australia has seen a surge in vitamin D testing of children, with similar trends reported for adults around the world. GPs are now being urged not to test for vitamin D unnecessarily. So when is low vitamin D a potential concern? And when might you need to get your levels tested?How much vitamin D do we need?Vitamin D also has many other roles, including helping our immune defences and contributing to DNA repair and cell differentiation.

Key Points: 


Australia has seen a surge in vitamin D testing of children, with similar trends reported for adults around the world. GPs are now being urged not to test for vitamin D unnecessarily. So when is low vitamin D a potential concern? And when might you need to get your levels tested?

How much vitamin D do we need?

    • Vitamin D also has many other roles, including helping our immune defences and contributing to DNA repair and cell differentiation.
    • We can thank the sun for most of our vitamin D. A chemical in our skin called 7-dehydrocholesterol is converted to vitamin D after contact with UVB radiation from the sun.
    • While we get some vitamin D also through our diet, this makes a relatively small contribution.
    • It’s difficult to get much more than one-third of our daily vitamin D requirement from diet without supplementation.

Why avoid vitamin D deficiency?

    • Prolonged, severe vitamin D deficiency will lead to softening of bone tissue and cause diseases such as rickets (children) and osteomalacia (adults).
    • However, avoiding low concentrations is likely to be good for many aspects of health, with consistent evidence suggesting benefits for infectious diseases and autoimmune conditions such as multiple sclerosis.

Who is at risk of deficiency?

    • The two main reasons for vitamin D deficiency typically relate to: 1. not getting (enough) vitamin D through sun exposure.
    • Deficiency risk can be high for anyone who is housebound, such as older or disabled people in residential care.
    • The risk of deficiency increases if we always cover our skin carefully by modest cultural dress, and also dark skin pigmentation is known to reduce vitamin D synthesis.

Am I getting enough sun exposure?

    • In Australia, it is possible to get enough vitamin D from the sun throughout the year.
    • Read more:
      Why you need more Vitamin D in the winter

      During winter, catching enough sun can be difficult, especially if you spend your days confined indoors.

    • This is because sunlight exposure can only help produce vitamin D if the UVB rays reach us at the correct angle.

Why does excess vitamin D testing matter?

    • Excessive testing is also a waste of health-care resources, with one single test costing about the same as a years’ worth of vitamin D supplementation.
    • Very often, we can make relatively small changes to our lifestyles to reduce the risks of vitamin D deficiency.